News headlines about Apellis Pharmaceuticals (NASDAQ:APLS) have trended somewhat positive on Friday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.1739917521519 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
APLS opened at $23.16 on Friday. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $1,198.37 and a price-to-earnings ratio of -6.31. Apellis Pharmaceuticals has a 1-year low of $12.45 and a 1-year high of $27.53.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Monday. JPMorgan Chase increased their target price on shares of Apellis Pharmaceuticals from $31.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, March 23rd. Finally, B. Riley assumed coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, February 8th. They set a “buy” rating and a $27.00 target price for the company. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $27.50.
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.